Please login to the form below

Not currently logged in
Email:
Password:

Novartis' omalizumab effective in chronic skin disease

Study backs extended use of asthma treatment Xolair

Novartis building 

Novartis' allergic asthma treatment Xolair could find a new role as a treatment for an allergic skin disease after encouraging results in a phase III trial.

The active ingredient in Xolair (omalizumab) has been found to be effective as a treatment for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU) in the study, reinforcing the findings of two earlier trials.

Novartis filed for approval of omalizumab a few weeks ago as a treatment for CSU, which is known as chronic idiopathic urticaria (CIU) in the US and has no approved treatment other than antihistamines. Current treatment generally has limited efficacy and often has to be given in very high doses to control symptoms.

The latest trial - called ASTERIA 1 - showed that patients treated with omalizumab had significantly less itching and reported improved quality of life compared to the placebo group, with benefits seen as early as one week after starting treatment. The alleviation of itch was sustained over 24 weeks, according to Novartis.

Omalizumab has already been a useful earner for Novartis for some time, with the Xolair asthma product posting sales of $289m in the first six months of the year, a 21 per cent increase on the same period of 2012.

Novartis has not suggested how much upside approval in CSU could have for the omalizumab franchise, although the company's head of pharmaceuticals David Epstein said earlier this year it is likely to be "substantial".

"This is a disease that is not well known by many, but devastating for patients," he said during the company's second-quarter results call.

"These patients … have severe itching [and] have angioedema. They very often cannot work and live in constant fear of unexpected attacks," noted Epstein.

He also pointed out that omalizumab sits well alongside Novartis' new psoriasis candidate secukinumab as the foundations of an interesting dermatology franchise.

Article by
Phil Taylor

7th October 2013

From: Research

Share

Tags

Related Hub content

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Healthy narratives?
In medical market research we see that most physicians are not early adopters, preferring to wait for their colleagues to adopt new medicines and practices before doing so themselves. There...
Allergies – Always a story
Saycomms looks into the seasonal trend of allergies stories in the media and the communication campaigns launched in UK in 2015....
When is sun safety doing more harm than good?
Say Communications analyses the impact of sun safety campaigns in the news and on consumers...

Infographics